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Abstract
Much attention is currently being devoted to questions of protein and RNA tertiary structures and to the quaternary ar-
rangement of the individual macromolecules in ribonucleoprotein (RNP) particles. In this article we describe two complementary
strategies that allow the identiﬁcation of RNA–protein contact sites in assembled, nonlabeled RNP particles after UV crosslinking.
The ﬁrst combines immunoprecipitation of UV-irradiated RNP particles under mildly denaturing conditions followed by primer-
extension analysis of the crosslinked (and thus coprecipitated) RNA. The second involves the puriﬁcation of crosslinked peptide–
oligonucleotide from RNP particles and the subsequent analysis of the crosslinked peptide and RNA by Edman degradation and
matrix-assisted laser desorption/ionization (MALDI)–mass spectrometry (MS), respectively. Although the ﬁrst approach provides a
rapid method for the exact identiﬁcation of RNA–protein contact sites in puriﬁed nonlabeled RNP particles, the latter adds valuable
information about potential RNA binding domains within proteins and, thus, about the arrangement of these proteins within the
quaternary structures of complex RNP assemblies. Recently, we applied both these strategies successfully to native puriﬁed
spliceosomal RNP. These methods may be generally applicable to the analysis of RNP complexes, especially as they avoid labeling
and reconstitution, both of which risk introducing artifacts.  2002 Elsevier Science (USA). All rights reserved.
1. Introduction
In the cell, RNA is rarely present in the absence of
proteins, and is often found as part of a stable RNP
complex. RNA–protein interactions within ribonucleo-
proteins (RNPs) are crucial for the function of these
particles in gene expression, gene regulation, and cell
function. An understanding of the molecular mecha-
nisms of these processes requires the identiﬁcation and
characterization of the RNA–protein interactions in-
volved. Owing to the diversity of RNA structures,
RNA–protein interactions are more complex than
DNA–protein interactions, involving more primary and
structural interaction motifs in the RNA and a greater
diversity of complementary structures in the protein [1–
4]. In addition, many proteins in complex ribonucleo-
protein assemblies (e.g., ribosomes or spliceosomes) do
not contain characterized RNA binding motifs. There-
fore, the introduction of general techniques useful for
detection of novel RNA–protein interaction sites in
RNPs represents an important step forward, since it is a
precondition for obtaining general insight into the mo-
lecular organization and function of such particles. For
example, before the atomic structures of ribosomes were
known [5–8], data from various biochemical studies [9–
11] had already led to models of the ribosome. These
data included RNA–protein interactions inferred from
biochemical results. Moreover, in the case of prokary-
otic ribosomes and their subunits, such data proved
useful in the initial interpretation of data from cryo
electron microscopy [12,13] and crystallization [14,15]
that ultimately led to the construction of three-dimen-
sional molecular models for these particles.
The combination of data derived from crosslinking
studies, from binding studies with puriﬁed components,
and from cocrystallization studies with images of the
spliceosomal HeLa U1 small nuclear (sn)RNP obtained
by electron cryomicroscopy at 10 A resolution has al-
lowed the deduction of the overall structure of the U1
snRNP [16]. The structure model obtained reveals the
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ring-shaped Sm core, which consists of the seven Sm
proteins (G, E, F, D1, D2, D3, B) assembled on the Sm
site of U1 snRNA, and it also shows the location of the
U1-snRNP-speciﬁc proteins A and 70K, bound respec-
tively to stems II and I of the U1 snRNA. The avail-
ability of structures of spliceosomal components at
atomic resolution is increasing steadily [17–20], yet
structural information on the spliceosome is still limited.
In the absence of further cocrystals and of binding
studies with puriﬁed components, crosslinking is a very
powerful tool in elucidating unknown or uncharacter-
ized RNA–protein interactions. A variety of crosslink-
ing techniques are available, and these have been used
successfully for the identiﬁcation of sites on the RNA to
which proteins crosslink within spliceosomal complexes
and other RNP particles. Crosslinking between RNA
and proteins has been obtained by UV irradiation at 254
nm, owing to the natural photoreactivity of the RNA
bases [21], or at higher wavelengths when photoreactive
base analogs such as 5-bromodeoxyuridine and 4-thio-
uracil were incorporated at speciﬁc sites [22, and refer-
ences therein]. Alternatively, chemical modiﬁcation of
the RNA through the ribose backbone [23] has also
proven useful in RNA–protein crosslinking by UV light.
All of these established approaches suﬀer from one
weakness: for the crosslinked sites to be mapped, the
RNA must be labeled with 32P, and hence the ribonu-
cleotide particles have to be reconstituted. Although
reconstitution of splicesomal particles has been used
successfully to increase the crosslinking yield by the in-
troduction of site-speciﬁc labels [24–28], it is subject to
diﬃculties associated with the eﬃciency of reconstitu-
tion and, more seriously, to the risk of artifacts: complex
ribonucleoprotein particles are diﬃcult to assemble in
vitro, and incomplete or incorrect assembly can result in
heterogeneous populations or false-positive results.
We have therefore focused on developing an ap-
proach that enables us to map RNA–protein crosslink-
ing sites in native, nonlabeled snRNP particles. This
approach was tested on puriﬁed U1 snRNP particles
and has since been extended to other snRNPs [29,30].
Our approach can be regarded as a potentially general
one, suitable for the detection of single and/or multiple
RNA–protein contact sites in native RNP particles. The
overall strategy is outlined schematically in Fig. 1, for
the example of U1 snRNPs. It comprises (i) the identi-
ﬁcation of the crosslinking sites on the RNA and the
identiﬁcation of the corresponding crosslinked protein
by immunoprecipitation combined with primer-exten-
sion analysis, and (ii) the identiﬁcation of the cross-
linking sites or regions within a protein and
identiﬁcation of the crosslinked RNA by mass spect-
rometry. The method depends on the numbers of anti-
bodies available for the diﬀerent proteins of the particle
and how eﬃciently each antibody precipitates its cor-
responding protein, especially under mildly denaturing
conditions (see below). In nonlabeled U1 snRNP we
have so far identiﬁed three diﬀerent crosslinking sites on
the RNA (Fig. 1). It is clear that the latter analysis re-
quires much more material, but, if successful, it enables
one to deﬁne putative RNA binding domains within the
crosslinked proteins, as outlined for the U1 70K protein
and for the Sm G protein in the heptameric Sm ring
(Fig. 1). In this article, we describe each approach in
detail, emphasizing the most critical steps. Most exam-
ples cited refer to puriﬁed U1 snRNP particles; other
systems are referred to where appropriate.
2. UV crosslinking of native snRNP particles
Total snRNPs are typically puriﬁed from HeLa nu-
clear extract by immunoaﬃnity chromatography by
using an H2O anti-m3G aﬃnity column [31,32]. Frac-
tions enriched in 25S [U4/U6.U5] tri-snRNPs, 20S U5
snRNPs, and 17S U2 and 12S U1 snRNPs are obtained
by subsequent glycerol-gradient centrifugation of the
total snRNPs. Glycerol-gradient-puriﬁed 17S U2 and
12S U1 snRNPs are applied to Mono Q ion-exchange
chromatography columns, and the U1 or U2 snRNP
fractions eluting from the Mono Q column are cross-
linked without further treatment. It is important that in
all further steps potassium chloride in buﬀers should be
avoided (see below), and that the concentration of buﬀer
ingredients that could decrease the crosslinking yield
(e.g., glycerol) should be kept as low as possible.
Typically, puriﬁed native snRNP particles are ad-
justed to a concentration of not more than 0.1 mg/ml
with a buﬀer containing 20 mM Tris–HCl (pH 7.0), 370
mM NaCl, 1.5 mM MgCl2, 0.5 mM dithiothreitol
(DTT), and 0.2 mM phenylmethylsulfonyl ﬂuoride
(PMSF), according to the salt concentration at which
U1 snRNP particles elute from the Mono Q column.
For identiﬁcation of crosslinking sites on the snRNA by
the primer-extension method, the samples are divided
into droplets of 25 ll on precooled 10-well multitest
slides (ICN Biomedicals, Inc., Aurora, OH). Alterna-
tively, droplets can be placed on a Paraﬁlm-wrapped
aluminum block on ice or in 0.5-ml Eppendorf tubes on
ice. In the last case, we use a maximum sample volume
of 10 ll in each tube. Siliconized glass plates or plastic
plates cannot be used, as puriﬁed snRNPs stick to these
surfaces. The glass slides are then placed on an alumi-
num block on ice (to minimize heating during irradia-
tion) and are UV-irradiated at a distance of 2 cm from
the UV source. Eppendorf tubes are mounted directly
under the lamps. For the 254-nm UV source, four 8-W
germicidal lamps (G8T5, Herolab, Wiesloch, Germany)
are used in parallel, mounted in a specially constructed
holder. We have observed that UV irradiation for longer
than 2–3 min does not increase the crosslinking yield
signiﬁcantly, and irradiation for longer than 3 min leads
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to a substantial loss of particles. Alternatively, a UV
Stratalinker 2400 (Stratagene, La Jolla, CA) can be
used, but, because of the diﬀerences in lamp geometry,
the crosslinking conditions have to be adjusted. For
large-scale crosslinking experiments we use glass dishes
with a planar surface. The depth of the sample solution
is around 1 mm; the diameter of the glass dish should be
chosen to match the sample volume correspondingly.
3. Analysis of the crosslinked products
3.1. Primer-extension analysis and immunoprecipitation
This approach includes three sets of experiments,
outlined below for the example of UV-irradiated U1
snRNP particles.
(i) Primer-extension analysis of the RNA derived from
UV-irradiated RNP particles: Potential RNA–protein
crosslinking sites are detected as discrete reverse tran-
scriptase stops after digestion of the crosslinked snRNP
particle with proteinase K, since a few amino acid resi-
dues remain covalently attached to the RNA at the sites
of crosslinking. The actual crosslinking site is taken to
be one nucleotide upstream of the stop site.
(ii) Primer-extension analysis of UV-irradiated naked
RNA, isolated from native particles: This control exper-
iment allows one to distinguish between, on the one
hand, reverse transcriptase stops that are due to UV-
induced strand breaks in the RNA, intra-RNA cross-
links, or stuttering of the reverse transcriptase (Fig. 2B,
triangles) and, on the other hand, reverse transcriptase
stops that are caused by a crosslinked protein.
(iii) Immunoprecipitation of crosslinked proteins under
mildly denaturing conditions and subsequent primer-ex-
tension analysis of the coprecipitated crosslinked RNA:
This experiment (Figs. 2A–C) allows the identiﬁcation
of a single RNA–protein crosslink. Immunoprecipita-
tion with antibodies against the speciﬁc proteins of U1
snRNP (e.g., anti-SmG antibody), under conditions
where the particle is completely dissociated, leads to
the isolation of a single crosslinked protein together
with a crosslinked RNA moiety. As in the other ex-
periments, the crosslinked site is detected by primer
extension after hydrolysis of the protein moiety with
proteinase K.
Fig. 1. Complementary strategy for identiﬁcation of protein–RNA crosslinking sites in native RNP particles as outlined for UV-irradiated U1
snRNPs. UV-irradiated U1 snRNP were analyzed with the aim to map crosslinking sites on the U1 snRNA and the proteins. Arrows in the U1
snRNA secondary structure indicate the crosslinking sites on the RNA as identiﬁed by our immunoprecipitation/primer-extension method [29,30];
these were in G28 and U30 in stem I and U127 in the Sm binding site of U1 snRNA. Arrows at the 3D protein models of the U1 70K protein [29] and
of the heptameric Sm protein ring [45] show the corresponding crosslinking sites within the protein as identiﬁed by Edman degradation combined
with matrix-assisted laser desorption/ionization (MALDI) mass spectrometry (MS) [29,30].
172 H. Urlaub et al. / Methods 26 (2002) 170–181
By comparing the reverse transcriptase patterns
found in the three experiments, it is usually possible to
identify unambiguously both the crosslinked protein
and the exact RNA nucleotide to which it is attached.
The experimental details for the successive steps are
as follows:
3.1.1. Preparation of crosslinked RNA
3.1.1.1. Crosslinked U1 snRNA derived from UV-irradi-
ated U1 snRNPs. A 50-ll sample of UV-irradiated na-
tive RNP particles is adjusted to 100 ll with sample
buﬀer (sample buﬀer refers to the buﬀer in which native
particles were ﬁnally puriﬁed, i.e., Mono Q ion-ex-
change buﬀer with salt concentration according to the
elution of U1 snRNPs, see above), and the sample is
incubated with proteinase K (Roche Diagnostics
GmbH, Mannheim, Germany) at a ﬁnal concentration
of 1 mg/ml for 30 min at 37 C in the presence of 1%
SDS. Note that SDS immediately precipitates in the
presence of potassium chloride, so sodium chloride in-
stead of potassium chloride is recommended for buﬀers
(see above). The RNA is extracted with phenol/chloro-
form, precipitated with 3 vol ethanol in the presence of
20 lg glycogen (Roche Diagnostics GmbH, Mannheim,
Germany), dissolved in 100 ll 0.3M sodium acetate,
again precipitated with 3 vol ethanol, dried under vac-
uum, and ﬁnally dissolved in 6:5 ll CE buﬀer (20 mM
cacodylate–KOH, pH 7.0, 0.2 mM EDTA) and stored at
)20 C. See Fig. 2A.
3.1.1.2. UV-crosslinked naked U1 snRNA isolated from
nonirradiated U1 snRNPs. A 50-ll sample of noncross-
linked native U1 snRNP particles is adjusted with Mono
Q buﬀer to 100 ll and incubated with proteinase K as
above. The nonirradiated naked U1 snRNA is recovered
as above (without glycogen) and ﬁnally dissolved in
50 ll buﬀer. Two 25 ll sample droplets are UV-irradi-
ated as above, precipitated with ethanol in the presence
of 20 lg glycogen, redissolved in 0.3M sodium acetate,
precipitated with ethanol, and ﬁnally stored in 6:5 ll CE
buﬀer at )20 C. See Fig. 2B.
3.1.1.3. Crosslinked U1 snRNA after immunoprecipita-
tion with antibodies speciﬁc for U1 snRNP proteins. The
most critical experiment during this analysis is the im-
munoprecipitation of crosslinked proteins under mildly
Fig. 2. Schematic representation of the procedure for identiﬁcation of RNA–protein crosslinking sites in native U1 snRNPs by primer-extension
analysis. (A) Primer-extension analysis of U1 snRNA derived from UV-irradiated U1 snRNP particles. (B) Primer-extension analysis of naked UV-
irradiated U1 snRNA. (C) Immunoprecipitation of U1 snRNP-speciﬁc proteins, with, e.g., an antibody against Sm proteins combined with primer-
extension analysis of the crosslinked and therefore coprecipitated U1 snRNA moiety. Black circles at the RNA indicate reverse transcriptase stop
sites due to a protein–RNA crosslinking event. Triangles mark stops sites that are caused by UV-induced strand breaks of the RNA, intra-RNA
crosslinks, or stuttering of the reverse transcriptase due to a particular RNA conformation.
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denaturing conditions. One characteristic of snRNP
particles is their strong protein–protein interactions, for
example, within the Sm core [33] or within an RNA-free
heteromeric U5 snRNP protein complex consisting of
the 220 K, 200 K, 116 K, and 40 K proteins [34]. To
precipitate speciﬁcally only a single protein that is
crosslinked to the RNA, strong protein–protein inter-
actions within the particles have to be disrupted com-
pletely by the use of SDS. Importantly, such denaturing
conditions must still allow the antibodies to retain their
reactivity during immunoprecipitation. For most of our
experiments, we use a ﬁnal SDS concentration of 1% (w/
v). However, when investigating the Sm protein–snRNA
crosslinking sites in UV-irradiated U1 snRNPs, we in-
crease the SDS concentration to 2% (w/v) (see below and
Fig. 3, compare 3B and 3C). Fifty microliters of UV-
crosslinked sample is adjusted with SDS to a ﬁnal SDS
concentration of 1 or 2% (w/v), respectively. The sam-
ples are incubated for 10 min on a shaker and then he-
ated for a minimum of 10 min at 70 C to allow
complete dissociation of the RNP complex. After cool-
ing to room temperature, Triton X-100 is added to a
ﬁnal concentration of 5% (v/v), and the sample volume
is then adjusted to 350 ll with phosphate-buﬀered saline
(20 mMNa2HPO4, pH 8.0, 130 mMNaCl). The samples
are incubated with diﬀerent U1 snRNP-protein-speciﬁc
antibodies bound to protein A–Sepharose (Amersham-
PharmaciaBiotech, Uppsala, Sweden) for 1 h at 4 C
with end-over-end rotation. The samples are washed
four times with phosphate-buﬀered saline (PBS) within
the same Eppendorf tube. For the ﬁnal washing step, the
slurry is transferred into a new Eppendorf tube, washed
Fig. 3. Immunoprecipitation of RNA–protein crosslinks under diﬀerent denaturing conditions combined with primer-extension analysis of the
coprecipitated RNA. (A) Primer-extension analysis of UV-irradiated naked U1 snRNA (lanes 1 and 2) compared with U1 snRNA derived from UV-
irradiated U1 snRNPs (lanes 3 and 4). Lanes 1 and 3 are controls with no UV irradiation. C, U, A, and G are dideoxy sequence markers. Nucleotides
within the Sm site are listed on the left. Reverse transcriptase stops that are due to putative RNA–protein crosslinks are denoted on the right. The
primer used was complementary to positions 143–152 of U1 snRNA. (B) Primer-extension analysis of U1 snRNA derived from UV-irradiated U1
snRNPs after immunoprecipitation with various antibodies against Sm proteins (SmF, SmG, SmD2, SmB) in the presence of 1% SDS (see text for
details). (C) primer-extension analysis of U1 snRNA derived from UV-irradiated U1 snRNPs with the same set of antibodies as in (B) but in the
presence of 2% SDS. The Sm site in (B) and (C) is identiﬁed as in (A).
174 H. Urlaub et al. / Methods 26 (2002) 170–181
one more time, and ﬁnally resuspended in sample buﬀer
containing 1% SDS (w/v). The washing procedure is
critical for a successful primer-extension analysis, for
two reasons. First, the additional washing step in an-
other Eppendorf tube reduces the nonspeciﬁc back-
ground level caused by RNA that might adhere to the
tube wall. Second, washing the samples with buﬀers
containing nonidet P-40 (NP-40) leads to a dramatic
increase of nonspeciﬁc background signals in the sub-
sequent primer extension (we have no explanation for
this). The RNA is extracted and recovered in the pres-
ence of glycogen as described above. Finally, the RNA is
stored in 3:5 ll CE buﬀer at )20 C. See Fig. 2C.
3.1.2. Primer-extension analysis
For a typical reverse transcriptase reaction, 1 ll of
crosslinked RNA is incubated with 0:25 ll 101HY
buﬀer (0.5 M Tris–HCl, pH 8.4, 0.6 M NaCl, 0.1 M
DTT), 0:5 ll 32P-labeled cDNA oligonucleotide, and
0:75 ll H2O for 60 s at 96 C. After cooling to room
temperature 2:15 ll H2O, 0:25 ll 101RTbuffer (0.5 M
Tris–HCl, pH 8.4, 0.6 M NaCl, 0.1 M MgCl2, 0.1 M
DTT), 0:1 ll dNTPs (5 mM in dGTP, dATP, dTTP, and
dCTP), and 0:1 ll reverse transcriptase (Seikagaku, Ja-
pan) are added to the reaction and incubated 45 min at
43 C. The transcripts are separated on a 50% (w/v) urea
and 9.6% polyacrylamide (20:1) sequencing gel in 1
Tris/borate/EDTA (pH 8.3). Gels are run at 65 W
throughout. To detect crosslinking sites adjacent to the
sites of the DNA primer, prerunning of the gel is rec-
ommended.
The choice of the primer is critical for the detection of
crosslinking sites. For investigation of crosslinking sites
within the U1 snRNP particle we use two diﬀerent
primers. One is complementary to nucleotide positions
63–77 in stem II of U1 snRNA, the other to nucleotide
positions 143–152 in the 30 stem–loop of U1 snRNA.
The ﬁrst primer proves to be useful in detection of two
crosslinking sites of the U1 70K protein in stem I of U1
snRNA [29], while the latter is used to detect the
crosslinking sites on the Sm site of U1 snRNA (Fig. 3)
[30]. The latter primer could not be used for identiﬁca-
tion of the U1 70K crosslinking sites, since these sites are
located too far downstream from the primer. In general,
RNA has to be probed with diﬀerent primers to obtain a
complete map of crosslinking sites.
Figs. 3A–C show all three sets of experiments per-
formed for identiﬁcation of the exact crosslinking sites
of Sm proteins on the U1 Sm site, thereby summarizing
the most critical points of the primer–extension as
mentioned above. First, by using a primer complemen-
tary to the 30 stem of U1 snRNA (positions 143–152),
reverse transcriptase stops that are diﬀerent from those
in the naked, UV-irradiated U1 snRNA can be detected
only in the 30 half of U1 snRNA (Fig. 3A, U128, G106,
U67). Additional reverse transcriptase stops, e.g., at C31
and A29 in stem–loop I, caused by U1 70K protein
crosslinking (data not shown; see, however, Ref. [29])
can be detected only by the use of a diﬀerent primer
(complementary to positions 63–77 of U1 snRNA).
Second, immunoprecipitation performed under condi-
tions where strong protein–protein interactions are not
completely disrupted leads to ‘‘false positives,’’ as shown
for the SmF protein in Fig. 3B. Immunoprecipitation
with anti-SmF, anti-SmG, anti-SmD2, or anti-SmB/B0
antibodies after dissociation of crosslinked U1 snRNPs
in the presence of only 1% SDS (w/v) shows the same
reverse transcriptase pattern for the SmF and SmG
proteins. When crosslinked U1 snRNPs are dissociated
in the presence of 2% SDS, a strong reverse transcriptase
stop at U128 is observed exclusively after immunopre-
cipitation with the anti-SmG protein antibody (Fig. 3C),
thus demonstrating that the SmG protein, but not the
SmF protein, is crosslinked to U129 in the Sm site of U1
snRNA [30].
3.2. Identiﬁcation of crosslinks sites at the molecular level
by protein mapping methods
In addition to the primer-extension method described
above, crosslinking of native or reconstituted particles
can be performed on a preparative scale to identify
peptide regions or domains that are in direct contact
with the RNA. The experimental approach can be di-
vided into four diﬀerent steps: (1) Puriﬁcation of cross-
linked peptide–RNA complexes by size-exclusion
chromatography, (2) puriﬁcation of crosslinked pep-
tide–oligonucleotides by reverse-phase (RP) high-per-
formance liquid chromatography (HPLC), (3) Edman
degradation of crosslinked peptide–oligonucleotide
complexes, and (4) matrix-assisted laser desorption/
ionization (MALDI) mass spectrometry (MS).
Edman degradation identiﬁes the crosslinked pro-
tein region in peptide–oligonucleotide complexes iso-
lated from UV-irradiated RNP particles [35–37]. This
information allows a ﬁrst insight into potential new
RNA binding domains of the proteins in contact with
RNA, and can be extremely helpful in deﬁning RNA
binding domains in the three-dimensional structures of
proteins that have not yet been cocrystallized with
their RNA substrate. In addition, MALDI-MS analy-
sis of the peptide–oligonucleotide complexes reveals
the crosslinked oligonucleotide part [29,38,39]. It
therefore complements the data derived from the im-
munoprecipitation or primer-extension method, and, if
a protein has multiple crosslink sites on the RNA (as
in the case of the U1 70K crosslinked to stem I of U1
snRNA), then it relates the crosslinking sites within
the protein to those on the RNA. Such an analysis
thus oﬀers a powerful tool for the reﬁnement of three-
dimensional structures that have not yet reached
atomic resolution.
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Because the successful analysis of the crosslinked
protein regions and the oligonucleotide strongly de-
pends on the homogeneity and purity of the peptide–
oligonucleotide complex, we focus in this report on the
two crucial chromatography steps necessary for the
isolation and puriﬁcation of peptide–oligonucleotide
crosslinks from native snRNP particles, namely, size-
exclusion chromatography and reverse-phase high-per-
formance liquid chromatography.
3.2.1. Puriﬁcation of crosslinked peptide–RNA complexes
by size-exclusion chromatography
In the ﬁrst puriﬁcation step, peptides that are cross-
linked to RNA have to be separated from the excess of
Fig. 4. Size exclusion chromatography for puriﬁcation of peptide–snRNA crosslinks. (A) Superdex 75 column elution proﬁle of U1 snRNA derived
from U1 snRNPs after digestion with trypsin under denaturing conditions. (B) Silver-stained SDS–PAGE of eluted fractions from UV-irradiated U1
snRNP particles digested with trypsin. (C) Silver-stained SDS–PAGE of eluted fractions from a nonirradiated sample digested with trypsin. (D)
Silver-stained SDS–PAGE from UV-irradiated U1 snRNPs digested with endoproteinase Glu-C.
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noncrosslinked peptides. This is achieved by size-exclu-
sion chromatography. Here, noncrosslinked U1 snRNA
coelutes with U1 snRNA that contains crosslinked
peptides, while noncrosslinked peptides are much
smaller and are therefore eluted later from the column.
If this step is not performed successfully, then further
puriﬁcation of peptide–RNA crosslinks and subsequent
identiﬁcation of the actual crosslinking sites is no longer
possible. Copuriﬁed noncrosslinked peptides will also
elute from the RP-HPLC in the ﬁnal puriﬁcation step
(see below) and interfere with the detection of peaks
containing peptide–oligonucleotide crosslinks.
Large-scale crosslinked U1 snRNP particles (see
above) are precipitated with 3 vol ethanol overnight in
30-ml Corex tubes (Kendro Laboratory Products,
Newtown, CT), washed with 80% ethanol, and air-dried
for 10 min. The pellet is redissolved in a small volume of
buﬀer (50 mM Tris–HCl, pH 8.0, 5 mM EDTA, 8 M
urea or 1% SDS) to disrupt any protein–protein inter-
action, transferred to an Eppendorf tube, and heated for
10 min at 70 C. After cooling to room temperature and
diluting the sample to an appropriate concentration of
urea or SDS at which endoproteinases are still active
(<1 M urea or <0.1% SDS), the particles are incubated
with, e.g., trypsin (sequencing grade, Roche Diagnostic
GmbH) or chymotrypsin (sequencing grade, Roche
Diagnostic GmbH) at a protease:substrate ratio of at
least 1:20 (w/w) overnight (16 h). We also tested other
endoproteinases for their ability to digest UV-irradiated
particles under these conditions, to obtain diﬀerent
crosslinked fragments. Earlier crosslinking experiments
with ribosomal subunits showed that the use of diﬀerent
endoproteinases led to the identiﬁcation of additional
crosslinking sites within the same protein [38]. Impor-
tantly, as is discussed below, the use of endoproteinases
other than trypsin or chymotrypsin on snRNP particles
causes serious problems during the further puriﬁcation
of the crosslinks.
To minimize the loading volume for the size-exclu-
sion chromatography, the samples are precipitated with
ethanol, washed, and dissolved in size-exclusion running
buﬀer (50 mM Tris–HCl, pH 7.8, 150 mM NaCl, 5 mM
EDTA) additionally containing 0.1% SDS or 1 M urea.
For size-exclusion chromatography we used a Superdex
75 HR column (AmershamPharmaciaBiotech, column
dimensions: 3:2 300 mm) in a SMART chromato-
graphy system (AmershamPharmaciaBiotech), at room
temperature. The practical loading range is 50 ll, and
the ﬂow rate was 40 ll=min. Fig. 4A shows a typical
example of U1 snRNA derived from UV-crosslinked U1
snRNPs eluting from the column after digestion of the
U1 snRNP-speciﬁc proteins with trypsin in the presence
of SDS. Note that the elution proﬁle of a U1 snRNA
sample derived from nonirradiated samples is identical.
Aliquots of each fraction are loaded directly onto 13%
SDS–PAGE and visualized by silver staining. Fig. 4B
shows the corresponding SDS–PAGE of U1 snRNA
derived from crosslinked U1 snRNPs, and Fig. 4C
shows a control of U1 snRNA derived from nonirradi-
ated U1 snRNPs. On both gels only U1 snRNA is de-
tectable, demonstrating that the protein moiety is
completely digested. The fraction with U1 snRNA de-
rived from irradiated particles (Fig. 4B) also contains
higher migrating bands, revealing putative peptide–U1
snRNA crosslinks. Fig. 4D shows the silver-stained
SDS–PAGE of eluted fractions from a similar experi-
ment in which endoproteinase Glu-C was used to gen-
erate peptide–U1 snRNA crosslinks. It is obvious that
under these conditions several U1 snRNP-speciﬁc pro-
teins are not digested and they comigrate within frac-
tions containing crosslinked and noncrosslinked U1
snRNA (Fig. 4D, e.g., the U1-speciﬁc protein A and the
Sm protein B/B0). The same is observed when the en-
doproteinase Lys-C (Roche Diagnostic GmbH) or Arg-
C (sequencing grade, Roche Diagnostic GmbH) is used.
However, the less stringent conditions required for ac-
tivity of these particular endoproteinases fails to induce
complete dissociation of the particles.
3.2.2. Puriﬁcation of crosslinked peptide–oligonucleotides
by reverse-phase high-performance liquid chromatography
The eluted fractions containing U1 snRNA and U1
snRNA with crosslinked peptides are precipitated with
ethanol overnight and dissolved in 150–200 ll of 2 mM
EDTA. The U1 snRNA is digested with ribonuclease T1
and/or ribonuclease A for 2 h at 52 C. Note that a large
excess of RNase T1 (up to 20–30 lg) is used, whereas in
the case of RNase A not more than 2–5 lg is used (see
below). After treatment with RNase, the samples are
adjusted to 50 mM Tris–HCl, pH 7.8, and subjected to a
second digestion with 1 lg trypsin or chymotrypsin at
37 C overnight. This step increases the yield of cross-
linked peptide–oligonucleotides eluting from RP-HPLC
[38]. We assume that after the ﬁrst round of digestion
before size-exclusion chromatography crosslinked pep-
tides have several missed cleavage sites, because of
protection of the crosslinked full-length snRNA. Such
large peptide–oligonucleotide complexes are more hy-
drophobic and therefore might stick to the C18-RP
column. A second digestion, performed after hydrolysis
of the RNA, generates smaller peptides that are rapidly
eluted from the C18-RP-HPLC column. Note that
RNases within the sample are also digested: while
RNase T1 is surprisingly stable against endoproteolytic
treatment, RNase A is digested and its peptides might be
eluted in HPLC and inﬂuence the detection of the pep-
tide–oligonucleotide crosslinks. Thus, the amount of
RNase A used must be kept as small as possible (see
above).
The digested sample ð200 llÞ is injected directly onto
a C18-RP-HPLC column (281TP5215, Vydac, Hesperia,
CA; column dimensions 2:1 mm i:d: 150 mm, particle
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size 5 lm, pore size 300 A) mounted in a SMART
chromatography system (AmershamPharmaciaBiotech)
equipped with 50-ml pumps. Elution begins at 5% Sol-
vent B (Fig. 5A). Solvent A is water containing 0.1% (v/
v) triﬂuoroacetic acid (TFA); solvent B is acetonitrile
containing 0.085% (v/v) TFA. In principle, in RP-HPLC
running at 5% solvent B, RNA oligonucleotides are
present in the ﬂow-through, while peptides and cross-
linked peptide–oligonucleotides are eluted at higher
concentrations of solvent B. Therefore, the gradient is
started after elution of the injection peak. A typical
gradient applied was: (1) isocratic elution of the injec-
tion peak at 5% solvent B for 30 min, (2) 5% solvent B to
45% solvent B for 120 min, (3) 45% solvent B to 80%
solvent B for 20 min. An additional isocratic step that
varies in time is performed at 10% solvent B, as larger
snRNA oligonucleotides always eluted at that percent-
age of solvent B (Fig. 5A). The gradient is continued
when the baseline is reached. Fractions eluting from the
column that exhibit strong absorbance at 220 and 260
nm are presumed to contain a crosslinked peptide–oli-
gonucleotide (Fig. 5A, marked by asterisks). These
fractions are dried under vacuum and stored at )20 C
until analysis by Edman degradation (Fig. 5B) and
MALDI-MS (Fig. 5C). Note that prolonged storage
times drastically reduce the amount of detectable
crosslinks in Edman degradation and MALDI-MS.
During RP-HPLC analysis of crosslinked samples,
multiple crosslinked peptide–oligonucleotides are al-
ways eluted from the column (Fig. 5A, asterisks). The
majority of the peaks contain peptides with the same site
crosslinked to RNA. The fractions diﬀer in peptide
length (incomplete proteolytic digestion) and in oli-
gonucleotide length (incomplete RNA hydrolysis). In
addition, multiple peaks are derived from one cross-
linked peptide–oligonucleotide and are due to diﬀerent
states of TFA denaturation. Note that strong absor-
bance at 280 nm is always indicative of contamination
by larger peptides or small proteins (e.g., RNase T1, Fig.
5A) and fractions showing this should not be analyzed.
3.2.3. Edman degradation
Crosslinked peptide–oligonucleotides are dissolved in
an appropriate volume of 50% acetonitrile containing
0.1% TFA, and two-thirds of the sample is subjected to
automated N-terminal sequencing (this was performed
on a Procise Sequencer, Applied Biosystems, Foster
City, CA). During Edman degradation the crosslinked
amino acid residue cannot be detected, owing to its
covalent modiﬁcation, and it is therefore identiﬁed as a
gap in the Edman degradation products. This is outlined
schematically in Fig. 5B for a tryptic fragment of the U1
70K protein crosslinked to U1 snRNA. N-Terminal
sequencing identiﬁes a peptide with the sequence
RVXVDVER. In each cycle except the third, amino
acids can be clearly identiﬁed. The sequence can be as-
signed to a tryptic fragment derived from U1 70K,
173RVLVDVER180. Within this oligopeptide, Leu-175 is
in the position of the nondetectable amino acid and is
therefore considered to be the actual crosslinking site
within the peptide.
3.2.4. Matrix-assisted laser desorption/ionization mass
spectrometry
The remaining one-third of the sample is analyzed by
mass spectrometry in a time-of-ﬂight (TOF) MALDI
mass spectrometer. As outlined schematically in Fig. 5C,
the diﬀerence between the mass of the crosslinked oli-
gonucleotide and that of the peptide (as determined by
Edman sequencing of the crosslinked peptide moiety)
allows determination of the nucleotide composition of
the crosslinked oligonucleotide. The exact calculation
procedure for the crosslinked oligonucleotide moiety of
isolated complexes is described in detail elsewhere
[29,38,39]. The RNA modiﬁcation database, http://
medlib.med.utah.edu/RNAmods/, provides several soft-
ware tools useful for calculations concerning RNA in
mass spectrometry.
Samples can be measured by two principal methods:
1. The sample ð0:5–0:8 llÞ in 50% acetonitrile, 0.1%
TFA is mixed with 1:2 ll of matrix solution (satu-
rated solution of a-cyano-4-hydroxycinnamic acid
(Sigma–Aldrich Co., St. Louis, MO)) in water:aceto-
nitrile 3:2, containing 0.1% (v/v) TFA on the target
and air-dried. Mass spectra are recorded on a VG-
TOFSpec (Fisons, Manchester, UK) in the linear
positive ion mode with an acceleration voltage of 22
kV by summing over 30–50 laser shots (N2-pulsed la-
ser, 337 nm, 4 ns) according to Thiede et al. [40].
2. Alternatively, 0:5 ll of the sample is mixed on a
stainless-steel sample plate with the same volume of
a 10 mg/ml solution of DHB (2,5-dihydroxybenzoic
acid, Sigma–Aldrich Co.) matrix in 50% acetonitrile
containing 0.1% TFA. The preparation is air-dried
and used for MALDI-TOF analysis on a Voyager
DE-STR (Applied Biosystems) without further pro-
cessing. The samples are measured in the reﬂector
mode, with acceleration voltage 20 kV, grid voltage
68%, delay time 250 ns, by summing over 300 laser
shots (N2-pulsed laser, 20 Hz, 337 nm).
Measuring in the reﬂector mode has the advantage
over the linear mode that monoisotopic masses of the
components can be considered. MALDI-MS in the lin-
ear mode does not allow the unambiguous diﬀerentia-
tion of C and U, since these diﬀer in mass by only one
mass unit. Thus, diﬀerent compositions of the cross-
linked oligonucleotide have to be considered (for details,
see Refs. [29,38,39]). Note that, for measuring in the
reﬂector mode, the use of DHB as matrix is recom-
mended, since a-cyano-4-hydroxycinnamic acid gives
poor or no results.
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Fig. 5. Final purifcation of peptide–oligonucleotide crosslinks and subsequent analysis of the actual crosslinking site. (A) RP-HPLC of peptide–
oligonucleotide crosslinks derived from UV-irradiated U1 snRNPs digested with trypsin and RNase A and T1. Asterisks mark fractions that were
considered to contain crosslinks. These fractions were subjected to automated N-terminal sequence analysis (see B) and MALDI-MS (see C). (B)
Schematic presentation of identiﬁcation of crosslinking sites within peptides by Edman degradation. During analysis of the Edman degradation
products the crosslinked amino acid cannot be detected. It is denoted with an . (C) Schematic presentation of analysis of the oligonucleotide moiety
in crosslinked peptide–oligonucleotide complexes. The mass of the crosslinked RNA moiety can be calculated from the mass diﬀerence of the
measured complex and the mass of the peptide moiety as determined by Edman degradation. From this mass diﬀerence the nucleotide composition
can be determined. Software tools are available from http://medlib.med.utah.edu/RNAmods/. (D) Summary of crosslinking data obtained by Ed-
mann degradation and MALDI-MS analysis from puriﬁed U1 70K peptide–U1 snRNA oligonucleotide complexes. The peptide containing the
crosslinked Tyr112 is derived from UV-irradiated U1 snRNPs after digestion with chymotrypsin, whereas that carrying the crosslinked Leu175, after
digestion with trypsin. In both cases a mixture of RNase A and T1 was employed.
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As summarized in Fig. 5D, the combination of Ed-
man degradation and MALDI-MS enabled us to relate
two crosslinking sites within the U1 70K protein to the
corresponding crosslinking sites in stem I of U1 snRNA.
4. Concluding remarks
Analysis of the molecular RNA–protein arrangement
in mammalian snRNP particles complements the exten-
sive characterization of their protein composition [41,42].
Our two-tracked approach contributes in two ways: (1) It
allows the rapid and exact identiﬁcation of RNA–protein
crosslinking sites in isolated snRNP particles. Although
it is not as sensitive as when labeled components are used,
it has the advantage that it can reveal multiple cross-
linking sites between one protein and its cognate RNA,
by the combination of primer-extension analysis and
immunoprecipitation. (2) It adds valuable data about
potential new RNA binding domains within the snRNP-
associated proteins. In this manner, we have demon-
strated that regions of the Sm1motif within the Sm B and
G proteins interact directly with RNA [30]. So far, the
biochemical characterization of Smmotifs 1 and 2 within
the Sm proteins has not proceeded beyond establishing
their involvement in protein–protein interactions among
the Sm proteins [43–45]. More recently, multivariate
statistical analysis of negative-stained electron micro-
scopic images and crystallization of Sm-like proteins
from the archaebacterium Archaeoglobus fulgidus [46,47]
revealed a seven-membered ring structure of the assem-
bled Sm proteins on an oligo(U) RNA stretch and,
consistent with our data, a direct interaction of a loop
structure (loop 3) within the Sm motif 1 of the Sm-like
proteins with the oligo(U) RNA.
Another feature of our approach is the possibility of
conﬁrming protein–RNA interactions in particles re-
constituted in vitro. Once a protein–RNA interaction in
native particles is established by our immunoprecipita-
tion or primer-extension method, crosslinking and sub-
sequent analysis of the RNA–protein crosslinking sites
in particles reconstituted in vitro should reveal similar
interaction patterns, thus conﬁrming the proper con-
formation and activity of reconstituted components.
Working with reconstituted particles also provides an
opportunity for the identiﬁcation of protein sites in
contact with RNA, especially when the yield of isolated
native particles might be too low.
Furthermore, with the availability of three-dimen-
sional cryo-EM structures of isolated snRNPs, deter-
mining where proteins interact with their cognate RNAs
is becoming crucial for the interpretation of these
structures. In the case of U1 snRNP, our approach has
proven a very useful tool for the identiﬁcation of hith-
erto uncharacterized protein–RNA interactions at the
molecular level (Figs. 1 and 5D). We identiﬁed two
distinct amino acids in the RNA binding domain of U1
70K directly contacting bases of two nucleotides in stem
I of U1 snRNA. On the basis of these molecular inter-
actions, we proposed a structural model of the protein–
RNA interactions that is reminiscent of the protein–
RNA interactions of other proteins containing RNA
binding domains like U1a and Sxl [29,48,49]. Our ap-
proach further demonstrated for the ﬁrst time that the
Sm-site RNA is in direct contact with the inner surface
of a heptameric Sm protein ring [30,45] and thus sup-
ports the assumption that the Sm-site RNA might tra-
verse the Sm protein ring. Such structural information
should be of value in the reﬁnement of three-dimen-
sional structures.
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